Coherus Oncology (CHRS) Revenue (2013 - 2026)

Coherus Oncology has disclosed Revenue across 13 years of filings, most recently posting $12.3 million for Q1 2026.

• Revenue for Q1 2026 came in at $12.3 million, up 61.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.9 million (up 47.99% YoY), and the FY2025 annual result was $42.2 million, up 59.81% from the prior year.
• Revenue came in at $12.3 million for Q1 2026 at Coherus Oncology, down from $12.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $91.5 million in Q4 2023 to a low of $2.3 million in Q1 2024.
• The 5-year median for Revenue is $12.7 million (2025), against an average of $32.3 million.
• Across the five-year window, Revenue tumbled 92.88% in 2024 and soared 229.25% in 2025, its largest moves.
• Coherus Oncology's Revenue stood at $45.4 million in 2022, then surged by 101.81% to $91.5 million in 2023, then sank by 91.55% to $7.7 million in 2024, then soared by 64.85% to $12.7 million in 2025, then retreated by 3.44% to $12.3 million in 2026.
• The last three Revenue figures came in at $12.3 million (Q1 2026), $12.7 million (Q4 2025), and $11.6 million (Q3 2025), per Business Quant data.